SecProbe.io

CORRESP
 1
 filename1.htm

 Bluejay Diagnostics, Inc.

 360 Massachusetts Avenue, Suite 203

 Acton, MA 01720

 November 25, 2025

 VIA EDGAR

 Securities and Exchange Commission
Division of Corporation Finance

 100 F Street, N.E.

 Washington, D.C. 20549

 Re: Bluejay Diagnostics, Inc.

 Registration Statement on Form S-3

 File No. 333-291042

 Request for Acceleration of Effectiveness

 Ladies and Gentlemen:

 Pursuant to Rule 461 of the General Rules and Regulations
under the Securities Act of 1933, as amended, Bluejay Diagnostics, Inc. (the " Company ") hereby requests that the Securities
and Exchange Commission accelerate the effectiveness of the above-referenced Registration Statement on Form S-3 (the " Registration
Statement "), and declare the Registration Statement effective as of 4:30 p.m., Eastern Time, on November 26, 2025, or as soon
thereafter as is practicable, or at such other time as the Company may orally request by telephone. The Company hereby authorizes each
of Brian O'Fahey and Helen Ferrall of Hogan Lovells US LLP, counsel to the Company, to make such request on its behalf.

 Please feel free to direct any questions or comments
concerning this request to Mr. O'Fahey at (202) 637-6541 or Ms. Ferrall at (202) 804-7696, and once the Registration Statement has
been declared effective, please notify Mr. O'Fahey or Ms. Ferrall by calling either of them at the same phone number.

 Very truly yours,

 Bluejay Diagnostics, Inc.

 /s/ Neil Dey

 By: 	Neil Dey Title:	President and Chief Executive Officer

CORRESP
 1
 filename1.htm

 Bluejay
Diagnostics, Inc.

 360
Massachusetts Avenue, Suite 203

 Acton,
MA 01720

 May
5, 2025

 VIA
EDGAR

 Securities
and Exchange Commission

 Division of Corporation Finance

 100
F Street, N.E.

 Washington,
D.C. 20549

 Re:
 Bluejay
 Diagnostics, Inc.

 Registration
Statement on Form S-3

 File
No. 333-286834

 Request
for Acceleration of Effectiveness

 Ladies
and Gentlemen:

 Pursuant
to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, Bluejay Diagnostics, Inc. (the " Company ")
hereby requests that the Securities and Exchange Commission accelerate the effectiveness of the above-referenced Registration Statement
on Form S-3 (the " Registration Statement "), and declare the Registration Statement effective as of 4:30 p.m., Eastern
Time, on May 7, 2025, or as soon thereafter as is practicable, or at such other time as the Company may orally request by telephone.
The Company hereby authorizes each of Brian O'Fahey and Helen Ferrall of Hogan Lovells US LLP, counsel to the Company, to make
such request on its behalf.

 Please
feel free to direct any questions or comments concerning this request to Mr. O'Fahey at (202) 637-6541 or Ms. Ferrall at (202)
804-7696, and once the Registration Statement has been declared effective, please notify Mr. O'Fahey or Ms. Ferrall by calling
either of them at the same phone number.

 Very
 truly yours,

 Bluejay
 Diagnostics, Inc.

 /s/
 Neil Dey

 By:
 Neil
 Dey

 Title:
 President
 and Chief Executive Officer

<DOCUMENT>
<TYPE>TEXT-EXTRACT
<SEQUENCE>2
<FILENAME>filename2.txt
<TEXT>
 May 2, 2025

Neil Dey
President and Chief Executive Officer
Bluejay Diagnostics, Inc.
360 Massachusetts Avenue, Suite 203
Acton, MA 01720

 Re: Bluejay Diagnostics, Inc.
 Registration Statement on Form S-3
 Filed April 29, 2025
 File No. 333-286834
Dear Neil Dey:

 This is to advise you that we have not reviewed and will not review your
registration
statement.

 Please refer to Rules 460 and 461 regarding requests for acceleration.
We remind you
that the company and its management are responsible for the accuracy and
adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action
by the staff.

 Please contact Nicholas O'Leary at 202-551-4451 with any questions.

 Sincerely,

 Division of
Corporation Finance
 Office of Industrial
Applications and
 Services
cc: Brian O'Fahey, Esq.
</TEXT>
</DOCUMENT>

CORRESP
1
filename1.htm

Bluejay Diagnostics, Inc.

360 Massachusetts Avenue, Suite 203

Acton, MA 01720

June 25, 2024

VIA EDGAR

Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

Re: Bluejay Diagnostics, Inc.

Registration Statement on Form S-1, as amended

File No. 333-280253

Request for Acceleration of Effectiveness

Ladies and Gentlemen:

Pursuant to Rule 461 of the General Rules and
Regulations under the Securities Act of 1933, as amended, Bluejay Diagnostics, Inc. (the “Company”) hereby requests
that the Securities and Exchange Commission accelerate the effectiveness of the above-referenced Registration Statement on Form S-1, as
amended (the “Registration Statement”), and declare the Registration Statement effective as of 4:30 p.m., Eastern Time,
on June 26, 2024, or as soon thereafter as is practicable, or at such other time as the Company may orally request by telephone. The Company
hereby authorizes each of Brian O’Fahey and Helen Ferrall of Hogan Lovells US LLP, counsel to the Company, to make such request
on its behalf.

Please feel free to direct any questions or comments
concerning this request to Mr. O’Fahey at (202) 637-6541 or Ms. Ferrall at (202) 804-7696, and once the Registration Statement
has been declared effective, please notify Mr. O’Fahey or Ms. Ferrall by calling either of them at the same phone number.

    Very truly yours,

    Bluejay Diagnostics, Inc.

    /s/ Neil Dey

    By:
    Neil Dey

    Title:
    President and Chief Executive Officer

CORRESP
1
filename1.htm

June 25, 2024

VIA EDGAR

Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, DC 20549

 RE: Bluejay Diagnostics, Inc. (CIK: 0001704287)

Registration Statement No.
333-280253 on Form S-1 (the “Registration Statement”)

Ladies and Gentlemen:

Pursuant to Rule 461 of the General Rules
and Regulations of the U.S. Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities
Act”), Aegis Capital Corp. hereby requests acceleration of the effective date of the above-referenced Registration
Statement so that it will become effective at 4:30 p.m. Eastern Time, June 26, 2024, or as soon thereafter as practicable.

Pursuant to Rule 460 under the Securities Act,
please be advised that we will distribute as many electronic copies of the proposed form of preliminary prospectus as appears to be reasonable
to secure adequate distribution.

By: AEGIS CAPITAL CORP.

    By:
    /s/ Robert Eide

    Name:
    Robert Eide

    Title:
    Chief Executive Officer

United States securities and exchange commission logo
June 24, 2024
Neil Dey
Chief Executive Officer
Bluejay Diagnostics, Inc.
360 Massachusetts Avenue, Suite 203
Acton, MA 01720
Re:Bluejay Diagnostics, Inc.
Registration Statement on Form S-1
Filed June 17, 2024
File No. 333-280253
Dear Neil Dey:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Benjamin Richie at 202-551-7857 with any questions.
Sincerely,
Division of Corporation Finance
Office of Industrial Applications and
Services
cc:       Brian C. O'Fahey

CORRESP
1
filename1.htm

December 22, 2023

VIA EDGAR

U.S. Securities and Exchange Commission

Division of Corporate Finance

Washington, DC 20549

    Re:
    Bluejay Diagnostics, Inc.

    Registration Statement on Form S-1 (Registration No. 333-275697),
as amended - Concurrence in Acceleration Request

Ladies and Gentlemen:

H.C. Wainwright & Co.,
LLC (“Wainwright”), solely acting as placement agent on a best efforts basis in an offering pursuant to the registration
statement on Form S-1 (333-275697), as amended (the “Registration Statement”), hereby concurs in the request by Bluejay
Diagnostics, Inc. that the effective date of the above-referenced registration statement be accelerated to 5:15 P.M. (Eastern Time), or
as soon as practicable thereafter, on December 27, 2023, pursuant to Rule 461 under the Securities Act. Wainwright affirms that it is
aware of its obligations under the Securities Act as they pertain to the best efforts offering pursuant to the Registration Statement.

    Very truly yours,

    H.C. WAINWRIGHT & CO., LLC

    By:
    /s/ Edward D. Silvera

    Name:
    Edward D. Silvera

    Title:
    Chief Operating Officer

CORRESP
1
filename1.htm

Bluejay Diagnostics, Inc.

360 Massachusetts Avenue, Suite 203

Acton, MA 01720

December 22, 2023

VIA EDGAR

Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

Re: Bluejay Diagnostics, Inc.

Registration Statement on Form S-1, as amended

File No. 333-275697

Request for Acceleration of Effectiveness

Ladies and Gentlemen:

Pursuant to Rule 461 of the General Rules and
Regulations under the Securities Act of 1933, as amended, Bluejay Diagnostics, Inc. (the “Company”) hereby requests
that the Securities and Exchange Commission accelerate the effectiveness of the above-referenced Registration Statement on Form S-1, as
amended (the “Registration Statement”), and declare the Registration Statement effective as of 5:15 p.m., Eastern Time,
on December 27, 2023, or as soon thereafter as is practicable, or at such other time as the Company may orally request by telephone. The
Company hereby authorizes Brian O’Fahey of Hogan Lovells US LLP, counsel to the Company, to make such request on its behalf.

Please feel free to direct any questions or comments
concerning this request to Mr. O’Fahey at (202) 637-6541, and once the Registration Statement has been declared effective,
please notify Mr. O’Fahey by calling him at the same phone number.

    Very truly yours,

    Bluejay Diagnostics, Inc.

    /s/ Neil Dey

    By:
    Neil Dey

    Title:
    President and Chief Executive Officer

United States securities and exchange commission logo
November 30, 2023
Neil Dey
President and Chief Executive Officer
Bluejay Diagnostics, Inc.
360 Massachusetts Avenue, Suite 203
Acton, MA 01720
Re:Bluejay Diagnostics, Inc.
Registration Statement on Form S-1
Filed November 21, 2023
File No. 333-275697
Dear Neil Dey:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Juan Grana at 202-551-6034 with any questions.
Sincerely,
Division of Corporation Finance
Office of Industrial Applications and
Services
cc:       Brian O'Fahey

CORRESP
1
filename1.htm

Bluejay Diagnostics, Inc.

360 Massachusetts Avenue, Suite 203

Acton, MA 01720

(844) 327-7078

June 15, 2023

VIA EDGAR

U.S. Securities and Exchange Commission

Division of Corporation Finance

Office of Industrial Applications and Services

100 F Street, N.E.

Washington, D.C. 20549

Attention: Jordan Nimitz

    Re:
    Bluejay Diagnostics, Inc

    Registration Statement on Form S-3 (File No. 333-272432)

    Request for Acceleration of Effective Date

To the addressee referred to above:

Pursuant to Rule 461 of the General Rules and
Regulations under the Securities Act of 1933, as amended, Bluejay Diagnostics, Inc. (the “Company”) hereby respectfully
requests that the U.S. Securities and Exchange Commission accelerate the effective date and time of the above referenced Registration
Statement on Form S-3 (the “Registration Statement”) and declare the Registration Statement effective as of 5:30 p.m.
Eastern Time on June 20, 2023, or as soon thereafter as practicable.

The Company requests that it be notified of
such effectiveness by a telephone call to Brian C. O’Fahey of Hogan Lovells US LLP at (202) 637-6541.

    Sincerely,

    Bluejay Diagnostics, Inc.

    By:
    /s/ Neil Dey

    Neil Dey

    President and Chief Executive Officer

    cc:
    Kenneth Fisher, Chief Financial Officer, Bluejay Diagnostics, Inc.

    Ryan McSeveney, Corporate Controller, Bluejay Diagnostics, Inc.

    Joseph Gilligan, Hogan Lovells US LLP

    Brian O’Fahey, Hogan Lovells US LLP

    David Will, Hogan Lovells US LLP

United States securities and exchange commission logo
June 15, 2023
Neil Dey
President and Chief Executive Officer
Bluejay Diagnostics, Inc.
360 Massachusetts Avenue, Suite 203
Acton, MA 01720
Re:Bluejay Diagnostics, Inc.
Registration Statement on Form S-3
Filed June 5, 2023
File No. 333-272432
Dear Neil Dey:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration.  We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Jordan Nimitz at 202-551-5831 with any questions.
Sincerely,
Division of Corporation Finance
Office of Industrial Applications and
Services
cc:       Brian O'Fahey

CORRESP
1
filename1.htm

BLUEJAY DIAGNOSTICS, INC.

360 Massachusetts Avenue, Suite 203

Acton, MA 01720

November 5, 2021

VIA EDGAR

U.S. Securities and Exchange Commission

Division of Corporate Finance

Washington, DC 20549

Attention: Tyler Howes

 Re: Bluejay Diagnostics, Inc.

 Registration  Statement on Form S-1

 Registration  No. 333-260029

Ladies and Gentlemen:

Pursuant to Rule 461 of the
Securities Act of 1933, as amended, Bluejay Diagnostics, Inc., a Delaware corporation (the “Company”), hereby respectfully
requests that the effective date for the Registration Statement referred to above be accelerated so that it will be declared effective
at 4:30 P.M. (Eastern Time) on November 9, 2021, or as soon thereafter as possible on such date.

    Very truly yours,

    Bluejay Diagnostics, Inc.

    By:
    /s/ Gordon Kinder

    Name:
    Gordon Kinder

    Title:
    Chief Financial Officer

CORRESP
1
filename1.htm

November 5, 2021

VIA EDGAR

U.S. Securities and Exchange Commission

Division of Corporation Finance

Washington, DC 20549

 Re: Bluejay Diagnostics, Inc.

 Registration  Statement on Form S-1 (Registration No. 333-260029)

 Concurrence  in Acceleration Request

Ladies and Gentlemen:

Dawson James Securities, Inc.
(“Dawson”), as representative of the underwriters for the referenced offering, hereby concurs in the request by Bluejay
Diagnostics, Inc. that the effective date of the above-referenced registration statement be accelerated to 4:30 p.m. (Eastern Time), or
as soon as practicable thereafter, on November 9, 2021, pursuant to Rule 461 under the Securities Act. Dawson affirms that it is aware
of its obligations under the Securities Act in connection with this offering.

In connection with this acceleration
request and pursuant to Rule 460 under the Securities Act, please be advised that there will be distributed to each underwriter or dealer,
who is reasonably anticipated to be invited to participate in the distribution of the securities, as many copies, as well as “e-red”
copies of the preliminary prospectus, as appears to be reasonable to secure adequate distribution of the preliminary prospectus.

The undersigned confirms that
it has complied with and will continue to comply with, and it has been informed or will be informed by participating dealers that they
have complied with or will comply with, Rule 15c2-8 promulgated under the Securities Exchange Act of 1934, as amended, in connection with
the above-referenced issue.

    Very truly yours,

    DAWSON JAMES SECURITIES, INC.

    By:
    /s/ Robert D. Keyser, Jr.

    Name:
    Robert D. Keyser, Jr.

    Title:
    CEO

CORRESP
1
filename1.htm

    Cavas S. Pavri

    202.724.6847

    cpavri@schiffhardin.com

    100 N. 18th Street

    Suite 300

    Philadelphia, PA 19103

    t 202.778.6400

    f 202.778.6460

    www.schiffhardin.com

    October 25, 2021

By EDGAR Submission

Securities and Exchange Commission

Division of Corporation Finance

Office of Real Estate & Construction

100 F Street, N.E.

Washington, D.C. 20549

 Re: Bluejay Diagnostics, Inc.

Registration Statement on Form S-1

Filed October 4, 2021

File No. 333-260029

Ladies and Gentlemen:

This letter is being submitted
on behalf of Bluejay Diagnostics, Inc. (the “Company”) in response to the comment letter, dated October 15, 2021, of
the staff of the Division of Corporation Finance (the “Staff”) of the Securities and Exchange Commission (the “Commission”)
with respect to the Company’s Registration Statement on Form S-1 filed October 4, 2021 (the “Registration Statement”).

The Company’s Amendment
No.1 to its Form S-1 Registration Statement (the “Amended Registration Statement”) has been submitted to the Commission.

For the Staff’s convenience,
we have repeated the Staff’s comment prior to the Company’s response in bold italics.

Draft Registration Statement on Form S-1

Dilution, page 31

1. Please
revise the presentation to disclose historical net tangible book value (deficit) prior to the presentation of pro forma net tangible book
value.

Response: The Registration
Statement has been revised to include the above referenced presentation.

*   *   *

Securities and Exchange Commission

Page 2

Should you have any questions
regarding the foregoing, please do not hesitate to contact Cavas Pavri at (202) 724-6847.

    Sincerely,

    SCHIFF HARDIN LLP

    /s/ Cavas Pavri

    By: Cavas Pavri

Enclosures

    cc:
    Gordon Kinder, Chief Financial Officer

    Ralph De Martino, Schiff Hardin LLP

United States securities and exchange commission logo
October 15, 2021
Neil Dey
Chief Executive Officer and President
Bluejay Diagnostics, Inc.
360 Massachusetts Avenue, Suite 203
Acton, MA 01720
Re:Bluejay Diagnostics, Inc.
Registration Statement on Form S-1
Filed October 4, 2021
File No. 333-260029
Dear Mr. Dey:
            We have reviewed your registration statement and have the following comment.
            Please respond to this letter by amending your registration statement and providing the
requested information.  If you do not believe our comment applies to your facts and
circumstances or do not believe an amendment is appropriate, please tell us why in your
response.
            After reviewing any amendment to your registration statement and the information you
provide in response to this comment, we may have additional comments.
Registration Statement on Form S-1
Dilution, page 31
1.Please revise the presentation to disclose historical net tangible book value (deficit) prior
to the presentation of pro forma net tangible book value.
            We remind you that the company and its management are responsible for the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action or absence of
action by the staff.
            Refer to Rules 460 and 461 regarding requests for acceleration.  Please allow adequate
time for us to review any amendment prior to the requested effective date of the registration
statement.
            You may contact Vanessa Robertson at 202-551-3649 or Sasha Parikh at 202-551-3627 if
you have questions regarding comments on the financial statements and related matters.  Please

 FirstName LastNameNeil Dey
 Comapany NameBluejay Diagnostics, Inc.
 October 15, 2021 Page 2
 FirstName LastName
Neil Dey
Bluejay Diagnostics, Inc.
October 15, 2021
Page 2
contact Tyler Howes at 202-551-3370 or Ada Sarmento at 202-551-3798 with any other
questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       Cavas S. Pavri, Esq.

CORRESP
1
filename1.htm

    100
                                            N. 18th Street

                                                        Suite
                                            300

                                                        Philadelphia,
                                            PA 19103

                                                        t
                                            202.778.6400

                                                        f
                                            202.778.6460

                                                        www.schiffhardin.com

        Cavas
        S. Pavri

    202.724.6847

    cpavri@schiffhardin.com

October 4, 2021

By EDGAR Submission

Securities and Exchange Commission

Division of Corporation Finance

Office of Real Estate & Construction

100 F Street, N.E.

Washington, D.C. 20549

 Re: Bluejay Diagnostics, Inc.

Amendment No. 1 to Draft Registration Statement
on Form S-1

Submitted September 8, 2021

CIK No. 0001704287

Ladies and Gentlemen:

This letter is being submitted
on behalf of Bluejay Diagnostics, Inc. (the “Company”) in response to the comment letter, dated September 24, 2021,
of the staff of the Division of Corporation Finance (the “Staff”) of the Securities and Exchange Commission (the “Commission”)
with respect to the Company’s Amendment No. 1 to its Draft Registration Statement on Form S-1 submitted September 8, 2021 (the “Draft
Registration Statement”).

The Company’s Form S-1
Registration Statement (the “Registration Statement”) has been submitted to the Commission.

For the Staff’s convenience,
we have repeated the Staff’s comment prior to the Company’s response in bold italics.

Amendment No. 1 to Draft Registration Statement on Form S-1

Prospectus Summary

Our Company, page 2

1. We
note your response to prior comment 4. Please revise to remove the statement that you could have potential FDA clearance in the fourth
quarter of 2022 as this statement is speculative.

Response: The Registration
Statement has been revised to delete the above referenced statement.

Securities and Exchange Commission

Page 2

Symphony Advantages, page
2

2. We
note your revised disclosure regarding the 2016 Japan study sponsored by Toray. Please revise to explain the significance of the chemiluminescent
enzyme immunoassay (CLEIA) method. For example, clarify whether this is the current standard or method for measuring serum IL-6 concentrations
in the blood

Response: The Company
has revised the referenced disclosure in the Registration Statement.

Symphony IL-6, page 48

3. We
note your revised disclosure in response to prior comment 11. Please revise to clarify if you are conducting a single clinical study at
the University of Texas Southwestern Medical Center and Parkland Memorial Hospital or if these are separate clinical studies. For each
clinical study, please revise to disclose the study endpoints and the number of patients you plan to enroll. Please also disclose which
clinical studies are being conducted at William P. Clements Jr. University Hospital and Zale Lipshy Pavilion Hospital, when they began,
the number of patients and the study endpoints.

Response: The Company
has revised the disclosure in the Registration Statement to address the Staff’s comment.

Intellectual Property, Proprietary Technology, page 50

4. We
note your revised disclosure in response to our prior comment 13. With respect your related patents in international territories, please
revise to disclose the type of patent protection granted for each technology such as composition of matter, use or process, and the patent
expiration dates.

Response: The Company
has revised the disclosure in the Registration Statement as follows (emphasis added):

“We do not currently
hold any patents directly. We rely on a combination either directly or through our license agreement with Toray of patent, copyright,
trade secret, trademark, confidentiality agreements, and contractual protection to establish and protect our proprietary rights. We have
licensed U.S. Patent Nos. 8,409,447 (“the ’447 patent”) and 8,821,813 (“the ’813 patent”). The ’447
patent is valid through at least February 2029 and is generally directed to a separation chip and a method for separating an insoluble
components from a suspension with the separation chip. The ’813 patent is valid through at least March 2028 and is generally directed
to a liquid-feeding chip, a liquid feeding method and analysis method. We have also licensed use or process patents covering the
inventions and/or subject matter of the ’447 and ’813 patents in various international territories including Japan, Canada,
China, Europe and South Korea, which are valid through at least February 2027.”

Notes to Condensed Consolidated Financial Statements

2. Significant Accounting Policies, page F-26

5. On
page 37 you disclose the receipt of a $75,000 grant from the Massachusetts Growth Capital Corporation and we note that you recognized
the full amount for the period ended June 30, 2021. Please disclose your accounting policy for grants received.

Response: The Company
has revised the disclosure in the Registration Statement to address the Staff’s comment.

* * *

Securities and Exchange Commission

Page 3

Should you have any questions
regarding the foregoing, please do not hesitate to contact Cavas Pavri at (202) 724-6847.

    Sincerely,

    SCHIFF HARDIN LLP

    /s/ Cavas Pavri

    By: Cavas Pavri

 Enclosures

 cc: Gordon Kinder, Chief Financial Officer

    Ralph De Martino, Schiff Hardin LLP

United States securities and exchange commission logo
September 24, 2021
Neil Dey
Chief Executive Officer and President
Bluejay Diagnostics, Inc.
360 Massachusetts Avenue, Suite 203
Acton, MA 01720
Re:Bluejay Diagnostics, Inc.
Amendment No. 1 to Draft Registration Statement on Form S-1
Submitted September 8, 2021
CIK No. 0001704287
Dear Mr. Dey:
            We have reviewed your amended draft registration statement and have the following
comments.  In some of our comments, we may ask you to provide us with information so we
may better understand your disclosure.
            Please respond to this letter by providing the requested information and either submitting
an amended draft registration statement or publicly filing your registration statement on
EDGAR.  If you do not believe our comments apply to your facts and circumstances or do not
believe an amendment is appropriate, please tell us why in your response.
            After reviewing the information you provide in response to these comments and your
amended draft registration statement or filed registration statement, we may have additional
comments.
Amendment No. 1 to Draft Registration Statement on Form S-1
Prospectus Summary
Our Company, page 2
1.We note your response to prior comment 4. Please revise to remove the statement that you
could have potential FDA clearance in the fourth quarter of 2022 as this statement is
speculative.

 FirstName LastNameNeil Dey
 Comapany NameBluejay Diagnostics, Inc.
 September 24, 2021 Page 2
 FirstName LastName
Neil Dey
Bluejay Diagnostics, Inc.
September 24, 2021
Page 2
Symphony Advantages, page 2
2.We note your revised disclosure regarding the 2016 Japan study sponsored by Toray.
Please revise to explain the significance of the chemiluminescent enzyme immunoassay
(CLEIA) method. For example, clarify whether this is the current standard or method for
measuring serum IL-6 concentrations in the blood.
Symphony IL-6, page 48
3.We note your revised disclosure in response to prior comment 11. Please revise to clarify
if you are conducting a single clinical study at the University of Texas Southwestern
Medical Center and Parkland Memorial Hospital or if these are separate clinical studies.
For each clinical study, please revise to disclose the study endpoints and the number of
patients you plan to enroll. Please also disclose which clinical studies are being conducted
at William P. Clements Jr. University Hospital and Zale Lipshy Pavilion Hospital, when
they began, the number of patients and the study endpoints.
Intellectual Property, Proprietary Technology, page 50
4.We note your revised disclosure in response to our prior comment 13. With respect your
related patents in international territories, please revise to disclose the type of patent
protection granted for each technology such as composition of matter, use or process, and
the patent expiration dates.
Notes to Condensed Consolidated Financial Statements
2. Significant Accounting Policies , page F-26
5.On page 37 you disclose the receipt of a $75,000 grant from the Massachusetts Growth
Capital Corporation and we note that you recognized the full amount for the period
ended June 30, 2021. Please disclose your accounting policy for grants received.
            You may contact Sasha Parikh at 202-551-3627 or Vanessa Robertson at 202-551-3649 if
you have questions regarding comments on the financial statements and related matters.  Please
contact Deanna Virginio at 202-551-4530 or Ada Sarmento at 202-551-3798 with any other
questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       Cavas S. Pavri, Esq.

United States securities and exchange commission logo
August 20, 2021
Neil Dey
Chief Executive Officer and President
Bluejay Diagnostics, Inc.
360 Massachusetts Avenue, Suite 203
Acton, MA 01720
Re:Bluejay Diagnostics, Inc.
Draft Registration Statement on Form S-1
Submitted July 22, 2021
CIK No. 0001704287
Dear Mr. Dey:
            We have reviewed your draft registration statement and have the following comments.  In
some of our comments, we may ask you to provide us with information so we may better
understand your disclosure.
            Please respond to this letter by providing the requested information and either submitting
an amended draft registration statement or publicly filing your registration statement on
EDGAR.  If you do not believe our comments apply to your facts and circumstances or do not
believe an amendment is appropriate, please tell us why in your response.
            After reviewing the information you provide in response to these comments and your
amended draft registration statement or filed registration statement, we may have additional
comments.
Draft Registration Statement on Form S-1
Industry and Market Data, page 0
1.Your statements that: (i) you have not independently verified the accuracy or
completeness of third party data, (ii)  your internal research has not been verified by any
third party and (iii) investors  are cautioned not to give undue weight to any such
information, projections, and estimates may imply an inappropriate disclaimer of
responsibility with respect to the third party information and internal research. Please
either delete these statements or specifically state that you are liable for such information.

 FirstName LastNameNeil Dey
 Comapany NameBluejay Diagnostics, Inc.
 August 20, 2021 Page 2
 FirstName LastName
Neil Dey
Bluejay Diagnostics, Inc.
August 20, 2021
Page 2
Prospectus Summary, page 1
2.We note your disclosure that your product may provide a market solution "if cleared,
authorized, or approved by the U.S. Food and Drug Administration." Please revise to
clearly disclose, if true, that you intend to label and distribute Symphony as an RUO
product in the U.S. while you pursue 510(k) clearance from the FDA to use Symphony
for in vitro diagnostic use.
3.Please revise your disclosure here and in the Business section to provide appropriate
context for various conclusions and predictions as to the performance of your product
candidates and revise and/or remove any statements that imply safety or efficacy as safety
and efficacy determinations are solely within the authority of the FDA or similar foreign
regulators. For example, we note statements that RUO use in Japan has resulted in
"validation of the symphony platform," that results from your device "appear to be as
accurate as those performed in a laboratory," that your diagnostic product "provide[s]
results within 20 minutes," "reduces test result time from days to minutes" and your
product candidate "will eliminate the number of operational ‘touch-points’ from ‘sample-
to-result’ from six to two." Please revise this disclosure and similar statements throughout
your prospectus to remove any suggestion that there is an expectation that your product
candidate will be effective or will have improved performance. You may provide a
summary of the data that you used to draw these conclusions but not the conclusions or
predictions, and such discussion is more appropriate in the Business section where full
and proper context can be provided.
4.We note your disclosure that you are "positioned now to complete the last regulatory
stages of development needed to move to commercialization in the United States." Please
revise to clarify where you currently are in the regulatory process and the material steps
that you need to complete, including, if applicable, any clinical trials that must be
conducted or regulatory applications that must be submitted.
5.We note your disclosure that Toray Industries is your development partner and investor.
Please revise to explain the nature of Toray Industries' investment in your company.
Based on your disclosure, it appears that Toray serves as a licensor and supplier
only. Please also revise your summary to clearly state that you license the core technology
used in your Symphony platform and test cartridge product candidates from Toray
Industries.
6.Please revise the Prospectus Summary and Risk Factors to highlight the auditor's
explanatory paragraph regarding your ability to continue as a going concern. Your
disclosures should describe the potential consequences to your business if you are unable
to raise additional financing.

 FirstName LastNameNeil Dey
 Comapany NameBluejay Diagnostics, Inc.
 August 20, 2021 Page 3
 FirstName LastName
Neil Dey
Bluejay Diagnostics, Inc.
August 20, 2021
Page 3
Use of Proceeds, page 27
7.We note your disclosure that you intend to use approximately $5.0 million to obtain
regulatory approvals.  Please revise to disclose for which product candidates you intend to
seek regulatory approval, in which jurisdictions and through which regulatory
pathway using the proceeds from this offering.
Business
Our Symphony Platform, page 42
8.We note your disclosure that the Symphony platform is an innovative and proprietary
technology platform that in clinical trials appears to provide rapid, highly sensitive,
accurate, and simple measurements of key diagnostic biomarkers found in whole blood.
Please revise to clarify if these clinical trials were conducted by the Company or a third
party. Please also expand your disclosure to include a description of how the clinical trials
were conducted and the results observed that would support the above statement.
Manufacturing, page 44
9.Please revise to highlight that pursuant to your agreement with Toray Industries, you are
required to use Toray to manufacture test cartridges for a period of three years.
Regulatory Strategy, page 45
10.Please provide the basis for your statement that your Symphony IL-6 product candidate
could also be used with confirmed COVID-19 illness. Please revise to disclose whether
you have tested your product candidate for this indication and, if so, disclose the results of
such testing.
11.We note your disclosure that your clinical studies are being conducted at The University
of Texas, Southwestern Medical Center, Dallas, Texas and Parkland Clinic, Dallas, Texas.
Please revise to disclose how many trials are being conducted and for each trial being
conducted when the trial began, the current status of the trial and when you expect the trial
to be completed.

 FirstName LastNameNeil Dey
 Comapany NameBluejay Diagnostics, Inc.
 August 20, 2021 Page 4
 FirstName LastName
Neil Dey
Bluejay Diagnostics, Inc.
August 20, 2021
Page 4
12.With respect to your table on page 46 showing your expected timeline for your product
candidates, it appears to be premature and speculative to provide the estimated time to
market for your product candidates given that it appears that you have yet to complete
material steps in order to commercialize your product candidates.  Please revise this table
to provide the status of FDA approval of your various product candidates, including
clinical trials or studies you must complete, when you began clinical trials or studies and
when you expect to complete them and whether you have submitted or when you intend to
submit an application for approval to the FDA. Please also explain to us why you have not
included Toray Industries next to your Symphony™ IL-6 product candidates. In this
regard, we note that you license technology related to Symphony and the detection
cartridges.
Intellectual Property, page 47
13.We note that you do not currently hold any patents directly but that you have an exclusive
license with Toray to use their patents and know-how related to your Symphony platform
and test cartridges. Please revise your intellectual property disclosure to clearly identify
each material licensed patent or patent family, the type of patent protection granted for
each technology such as composition of matter, use or process, the specific products or
product candidates, product groups and technologies dependent on each patent, and the
patent expiration dates and applicable jurisdictions, including any foreign jurisdictions.
License Agreement, page 47
14.We note that you intend to file as an exhibit a Lease and Supply Agreement with Toray
Industries.  If this is not the license agreement that you have with Toray Industries, please
file the license agreement as an exhibit to your registration statement pursuant to Item
601(b)(10) of Regulation S-K.
15.We note your disclosure that you are required to pay a 15% royalty fee based on a
percentage of “Net Sales” of products. Please revise to disclose the royalty term.
Description of Our Securities, page 72
16.We note that you refer shareholders to, in part, the applicable provisions of the Delaware
General Corporation Law. It is not appropriate to qualify your disclosure by reference to
information that is not included in the filing or filed as an exhibit. Please revise
accordingly.
Recent Sales of Unregistered Securities., page II-2
17.Please revise your disclosure to name the persons or identify the class of persons to whom
the securities were sold. Refer to Item 701(b) of Regulation S-K.

 FirstName LastNameNeil Dey
 Comapany NameBluejay Diagnostics, Inc.
 August 20, 2021 Page 5
 FirstName LastName
Neil Dey
Bluejay Diagnostics, Inc.
August 20, 2021
Page 5
General
18.Please provide us with copies of all written communications, as defined in Rule 405 under
the Securities Act, that you, or anyone authorized to do so on your behalf, present to
potential investors in reliance on Section 5(d) of the Securities Act, whether or not they
retain copies of the communications.
            You may contact Sasha Parikh at 202-551-3627 or Vanessa Robertson at 202-551-3649 if
you have questions regarding comments on the financial statements and related matters.  Please
contact Deanna Virginio at 202-551-4530 or Ada D. Sarmento at 202-551-3798 with any other
questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       Cavas S. Pavri, Esq.